LUMIBIRD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.6 EUR | -3.08% |
|
-9.68% | +3.45% |
| Apr. 23 | Lumibird: over 7% growth in quarterly sales | CF |
| Mar. 13 | Lumibird: EBITDA improved by 10% in 2023 | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +3.45% | 307M | - | ||
| +7.96% | 220B | B | ||
| +7.04% | 185B | B- | ||
| +11.00% | 133B | B- | ||
| +26.78% | 107B | A- | ||
| -0.57% | 62.91B | A- | ||
| +16.22% | 53.34B | B+ | ||
| -1.89% | 47.71B | B+ | ||
| -1.80% | 40.29B | A | ||
| +10.36% | 39.57B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LBIRD Stock
- Ratings LUMIBIRD
